medicalxpress.com - Cancer drugs work because they're toxic, but that's also why they afflict healthy cells, producing side effects that can compromise their efficacy. Nobuhide Ueki thinks he may have found a way to get the drugs to selectively target only the cancer cells, and his team's patent-pending research is the subject of a paper entitled "Selective cancer targeting with prodrugs activated by histone deacetylases and a tumour-associated protease," to be published on November 5 in Nature Communications .
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.